74
Participants
Start Date
December 1, 2024
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2028
Tislelizumab+SOX
"OX: S-1 dosing based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-\<1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 6 cycles.~Tislelizumab: 200mg IV, day 1, Q3W, for a total of 6 cycles. HIPEC: Docetaxel 75mg/m² in 3500ml normal saline, at 43°C for 60 minutes."
Southwest Hospital, China
OTHER